poisar

Stocks · News reference

Pacira BioSciences Successfully Transitions PCRX-201 To A Scalable Commercial Manufacturing Process In The U.S.; Topline Data From Part A Of Phase 2 ASCEND Study Remains On Track For End Of 2026

Jul 27, 2026, 12:03 PMBenzinga Newsdesk

With drug product from the new manufacturing process now available, the first patient has been enrolled in Part B of the Phase 2 ASCEND study. Enrollment in Part A of ASCEND concluded in June, with topline data expected

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

PCRX
Source
benzinga
Observed
Jul 27, 2026, 12:03 PM
Checked
Jul 27, 2026, 12:03 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 6, 2026, 12:16 PMBenzinga Newsdesk

    Pacira Biosciences Publishes 2-Yr Phase 1 Results In Annals Of Rheumatic Diseases For PCRX-201 Gene Therapy In Moderate To Severe Knee Osteoarthritis, Showing Tolerability And Improvements In Pain, Stiffness, And Function

    — A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerated in patients with moderate-to-severe knee osteoarthritis —— Exploratory clinical outcome measures showed improvements

    Read original at benzinga
    PCRX